Varicella zoster virus the ACIP recommended a second dose of vaccine before school entry to ensure the maintenance of high levels of varicella immunity. In 2006, the United States Food and Drug Administration approved Zostavax for the prevention of shingles. Zostavax is a more concentrated formulation of the Varivax vaccine, designed to elicit an immune response in older adults whose immunity to VZV wanes with advancing age. A systematic review by the Cochrane Library shows that Zostavax reduces the incidence of shingles by almost 50%. Shingrix is a "V. zoster" vaccine developed by GlaxoSmithKline which was approved in the United States by the
Center for Scientific and Technical Creativity of the Youth subsidiaries of Komsomol "raikoms". The Centers enjoyed various benefits, including no taxes and only 3% contribution to the all-union fund. The fortunes of quite a few "new Russians", notably Mikhail Khodorkovsky arose from these Centers. The Centers continue to exist in modern Russia. Similar establishments were the Foundations of Youth Initiatives (фонды молодёжных инициатив, ФМИ). Center for Scientific and Technical Creativity of the Youth Centers for Scientific and Technical Creativity of the Youth , NTTM) were established in the late Soviet Union during "perestroika" as enterprises whose goal was commercialization of science and technology. Other translations of the Russian term